A role for EMT in CD73 regulation in breast cancer

CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasmim, Meriem, Berchem, Guy, Janji, Bassam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718558/
https://www.ncbi.nlm.nih.gov/pubmed/36465484
http://dx.doi.org/10.1080/2162402X.2022.2152636
_version_ 1784843115468685312
author Hasmim, Meriem
Berchem, Guy
Janji, Bassam
author_facet Hasmim, Meriem
Berchem, Guy
Janji, Bassam
author_sort Hasmim, Meriem
collection PubMed
description CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT.
format Online
Article
Text
id pubmed-9718558
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97185582022-12-03 A role for EMT in CD73 regulation in breast cancer Hasmim, Meriem Berchem, Guy Janji, Bassam Oncoimmunology Author’s View CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT. Taylor & Francis 2022-11-30 /pmc/articles/PMC9718558/ /pubmed/36465484 http://dx.doi.org/10.1080/2162402X.2022.2152636 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Hasmim, Meriem
Berchem, Guy
Janji, Bassam
A role for EMT in CD73 regulation in breast cancer
title A role for EMT in CD73 regulation in breast cancer
title_full A role for EMT in CD73 regulation in breast cancer
title_fullStr A role for EMT in CD73 regulation in breast cancer
title_full_unstemmed A role for EMT in CD73 regulation in breast cancer
title_short A role for EMT in CD73 regulation in breast cancer
title_sort role for emt in cd73 regulation in breast cancer
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718558/
https://www.ncbi.nlm.nih.gov/pubmed/36465484
http://dx.doi.org/10.1080/2162402X.2022.2152636
work_keys_str_mv AT hasmimmeriem aroleforemtincd73regulationinbreastcancer
AT berchemguy aroleforemtincd73regulationinbreastcancer
AT janjibassam aroleforemtincd73regulationinbreastcancer
AT hasmimmeriem roleforemtincd73regulationinbreastcancer
AT berchemguy roleforemtincd73regulationinbreastcancer
AT janjibassam roleforemtincd73regulationinbreastcancer

Ejemplares similares